NASDAQ:ARWR News 8 December 2025 - 7 January 2026

NEW YORK, December 30, 2025, 13:47 ET — Regular session Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares were down 3.6% at $67.09 at 1:47 p.m. ET on Tuesday, after trading between $65.94 and $69.95. The stock’s drop came as biotech weakened but the wider market held steady, a setup that can amplify moves in higher-volatility drug developers. The SPDR S&P Biotech ETF (XBI) fell 1.3% and the iShares Nasdaq Biotechnology ETF (IBB) dropped 1.1%, while the S&P 500 tracker SPY was flat and the Nasdaq-100 proxy QQQ edged higher. The timing matters because Arrowhead is heading into an early-January news window where

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is seeing a sharp pullback in Tuesday trading (Dec. 16, 2025), with shares recently changing hands around $62—down roughly 9% from the prior close—after hitting an intraday low near $59.76. That drop may look dramatic in isolation, but it’s landing on top of an unusually eventful stretch for the RNA interference (RNAi) biotech: Arrowhead just transitioned into a commercial-stage story after its first FDA approval, picked up an FDA Breakthrough Therapy designation for a follow-on indication, and kicked off a new Alzheimer’s-related clinical program—three ingredients that tend to increase both upside narratives and day-to-day volatility

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is ending 2025 in rare biotech air. The RNA interference (RNAi) specialist has secured its first U.S. drug approval, locked in a multibillion‑dollar licensing deal with Novartis, and just dosed the first subjects in a new Alzheimer’s disease trial — all while its share price hovers near record highs. Arrowhead Pharmaceuticals, Inc.+2Arrowhead Pharmaceuticals+2 As of intraday trading on December 9, 2025, Arrowhead Pharmaceuticals stock trades around $69 per share, giving the company a market value in the $9–9.5 billion range. That’s up dramatically from under $10 per share at its 52‑week low, and represents a